Pharmacodynamic optimization of beta-lactams in the patient care setting.
about
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsEvaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.Spinal versus General Anaesthesia in Postoperative Pain Management during Transurethral Procedures.Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceDoripenem: position in clinical practice.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Current treatment of community-acquired pneumonia.Antimicrobial Stewardship in the Emergency Department: Challenges, Opportunities, and a Call to Action for Pharmacists.Optimizing the use of carbapenems in the face of increasing Gram-negative resistanceOptimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapyPharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.
P2860
Q33552161-2EEF2C96-C7D7-4A31-AB68-9497A4A8F164Q34433108-75BFE008-01F9-4DB5-AA6E-F21C8AC86086Q34490565-B2986B37-BC61-43B0-9396-500A27D98E7AQ34974577-EFB49F91-9292-49A3-8D57-FF32339C9E10Q35367797-CB5CD4C5-2555-416D-A169-6D062AFE3A64Q35908084-B3AAFB55-C2F4-41E4-AB9B-663B2FFFA933Q36329228-4056838A-A5C6-4320-952B-9ED9ACB895C0Q37503320-BEB0022B-5E20-4A85-B78E-374A8BD76B62Q37867260-7AA1B652-001C-422B-BFD0-6C1693967FBDQ38073197-68E58B6C-7D24-4E35-B78E-E723CF046CB0Q38105639-ADFC1DD8-CECC-437B-AB96-6DB4B162AB57Q38512185-DFBDB187-5CDA-45AF-B9B3-78CE59F1483CQ38574332-21D41AFC-37E1-4782-B493-C0A70E44AF9FQ39344408-E4F70C0C-7CDB-4C6B-8974-25EE08949DCDQ40087256-30E01108-7101-408F-B393-DCCFCD5F60BAQ40375664-0DAAEE7A-2DCF-4F73-8861-0E1576DE33B4Q40749626-C23C589F-907D-4DE6-8624-483A06FC09FBQ41435865-C6545C28-A093-409C-9EAB-D9C25E2B1E92Q53654914-002140F5-13E9-49C5-86B5-DEF197B3FB91
P2860
Pharmacodynamic optimization of beta-lactams in the patient care setting.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@en
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@nl
type
label
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@en
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@nl
prefLabel
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@en
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@nl
P2860
P921
P356
P1433
P1476
Pharmacodynamic optimization of beta-lactams in the patient care setting.
@en
P2093
David P Nicolau
P2860
P2888
P356
10.1186/CC6818
P478
12 Suppl 4
P577
2008-05-21T00:00:00Z